This mechanism is supported by the outcome of CANTOS trial showing that anti-IL-1β antibodies reduced MACE in CVD patients (Ridker et al., 2017) and by a previous study showing the role of IL-18 in atherosclerosis in mice (Whitman et al., 2002). The gene discussed is IL1B; the disease is atherosclerosis.